Semaglutide CAS 910463-68-2 API

How does Semaglutide CAS 910463-68-2 API compare to other weight-loss medications?

The largest clinical trial studying semaglutide in adults showed an average weight loss of about 15% of initial body weight over 68 weeks (almost 16 months). Over the same length of time in another study, adolescents lost 15% of their initial body weight on average.

There are several oral weight loss pills available. Oral weight-loss medications tend to be less expensive than the injectable options. But you may not lose as much weight.

Phentermine: Phentermine (Adipex-P) is a popular oral weight-loss medication that has been around since 1959. It's approved for short-term use (a few weeks), and it's inexpensive. However, it's possible to develop a tolerance to the medication where it's no longer working for you. Plus, it's a controlled substance.

Qsymia: Phentermine is also available in combination with topiramate under the brand name Qsymia. Compared to phentermine alone, Qsymia can be taken for a longer period of time. Study results have shown average weight loss ranging from about 5% (at lower doses) to around 10% (at higher doses).

Contrave: Contrave (bupropion / naltrexone) is another medication used for weight loss. One study showed that people taking Contrave in combination with diet and exercise lost an average of about 9% of their baseline body weight after 56 weeks. Contrave also has several drug interactions to consider.

Who can use Semaglutide CAS 910463-68-2 API for Weight Loss?

Semaglutide for weight loss is approved to be used in adults and children 12 years of age and older based on their body mass index (BMI) and the presence of certain health conditions.

Semaglutide (Wegovy) is used in addition to diet and exercise for long-term weight management in:

Adults who are either obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol levels.
Adolescents 12 years and older with an initial BMI at or above the 95th percentile for age and sex (based on growth charts).
Semaglutide (Wegovy) is also approved In adults, to reduce the risk of heart attack, stroke and heart-related death in people with cardiovascular (heart, blood vessel) disease with either obesity or overweight.
You can learn how to calculate an adult BMI here. Have your child's pediatrician determine their BMI percentile based on the current charts.

Other prescription drugs that also contain semaglutide are Ozempic (injection) or Rybelsus (oral tablets). These brands are only approved to treat type 2 diabetes, together with diet and exercise, and are not specifically approved for weight loss, but can lead to weight loss.

Semaglutide (Ozempic) is also approved to help protect the heart and lower the risk for heart attack, stroke or heart-related death in adults with type 2 diabetes and heart disease.

How Long Does Semaglutide CAS 910463-68-2 API take to work?

You may see some weight loss in the 4 weeks of semaglutide treatment, but the full effect can take several months. After 68 weeks, adults lost about 35 lbs (15.9 kg) in studies, on average.

Your doctor will slowly increase your dose when you start treatment to help lessen stomach side effects like nausea and diarrhea. It typically takes about 17 weeks to reach your final maintenance dose of semaglutide.

Studies conducted by the manufacturer over 68 weeks show that, on average, adults using semaglutide lost about 35 lbs (15.9 kg), or about 15% of their body weight. In contrast, 31% of people using a placebo (inactive treatment) lost about 6 lbs (2.7 kg), or about 2.5% of their body weight.

In children 12 years and older, semaglutide reduced their body mass index (BMI) by 16.1% after 68 weeks compared to a 0.6% reduction in the placebo group. Plus, the BMI was reduced by at least 5% in 77% of children receiving semaglutide compared to 20% receiving a placebo.

The Science BehindSemaglutide CAS 910463-68-2 API Weight Loss Effects

We believe in the power of science-backed treatments, and Semaglutide is no exception. This medication targets the intricate interplay of hormones, neurotransmitters, and neural circuits that regulate appetite and metabolism.

Enhancing Satiety and Appetite Control
Receptors are abundant in areas of the brain responsible for appetite regulation. Semaglutide activates these receptors, leading to increased feelings of fullness and reduced hunger. This means you're more likely to make mindful food choices and consume fewer calories, a fundamental aspect of successful weight loss.

Slowing Gastric Emptying

Semaglutide goes beyond appetite suppression by slowing down the rate at which your stomach empties. This results in a prolonged feeling of satiety after meals, curbing your cravings and helping you resist the urge to overeat.

Modulating Reward Pathways

Semaglutide's influence extends to the brain's reward centers, which are responsible for the pleasurable sensations associated with food. By targeting these neural circuits, Semaglutide helps dampen the allure of high-calorie, indulgent foods, making it easier to stick to your nutritional plan.

Semaglutide CAS 910463-68-2 API in Patients with High Hematocrit and Hemoglobin Levels

The application of semaglutide in patients with elevated hematocrit and hemoglobin levels introduces a nuanced layer to its therapeutic spectrum, especially considering the implications of these hematological parameters on cardiovascular health. High hematocrit and hemoglobin levels, indicative of polycythemia, can increase blood viscosity, thereby elevating the risk of thrombosis and vascular complications.

The impact of semaglutide on hematocrit and hemoglobin levels is a topic of emerging interest, driven by the understanding that metabolic disorders can influence various hematological parameters. Preliminary data suggest that GLP-1 receptor agonists, including semaglutide, may have a neutral or potentially beneficial effect on these levels. However, the mechanisms underlying these effects are not fully elucidated and warrant further investigation. Potential explanations include semaglutide's role in improving metabolic control, which may indirectly influence erythropoiesis and red blood cell turnover.

Given the cardiovascular risks associated with high hematocrit and hemoglobin levels, the use of semaglutide in such populations requires careful consideration. It involves assessing the potential benefits of metabolic improvement against the theoretical risks related to blood viscosity and thrombosis. Clinicians must adopt a vigilant approach, involving regular monitoring of hematological parameters and cardiovascular signs and symptoms, to promptly address any adverse trends.

The management of patients with elevated hematocrit and hemoglobin levels on semaglutide therapy also emphasizes the importance of a holistic treatment strategy. This strategy may include lifestyle interventions, such as hydration and smoking cessation, and the use of aspirin or other antithrombotic agents in patients at high risk of vascular events. The decision to initiate or continue semaglutide treatment in this context should be based on a comprehensive risk-benefit analysis, taking into account the individual patient's cardiovascular risk profile and the potential impact of improved metabolic control on overall health.

The Link Between Semaglutide CAS 910463-68-2 API and Blood Pressure